40
Participants
Start Date
November 14, 2024
Primary Completion Date
November 14, 2025
Study Completion Date
December 30, 2028
Pre-operative chemotherapy
Patients will undergo pre-operative drug treatment (any chemotherapy drug or immunotherapy drug are accepted).
Robotic radical gastrectomy after neoadjuvant therapy
"Eligible participants must have stage III resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma based on imaging studies such as ultrasound endoscopy, CT, or MRI.~Patients will receive 3-4 cycles of neoadjuvant therapy, followed by imaging evaluations to assess the treatment response and determine eligibility for radical D2 gastrectomy. Within 2-6 weeks of the final neoadjuvant treatment cycle, eligible patients will undergo robotic radical gastrectomy."
RECRUITING
First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing
Jiangsu Cancer Institute & Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Affiliated Hospital of Nanjing University of Chinese Medicine
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER